Mandate

Vinge advises Biotage in connection with RWK Bidco’s public tender

April 22, 2025 M&A

On 22 April 2025, RWK Bidco AB, a newly formed company indirectly wholly owned by KKR Funds, announced a public tender offer to the shareholders in Biotage AB to tender all ordinary shares in Biotage to RWK Bidco at a price of SEK 145 in cash per ordinary share.

Biotage is a global supplier and solutions partner to a wide range of customers within drug discovery and development and analytical testing. Headquartered in Sweden, Biotage operates globally serving over 80 countries. The company is listed on Nasdaq Stockholm. The offer values Biotage to approximately SEK 11,607 million based on the total number of ordinary shares in Biotage.

Vinge’s team mainly consists of Dain Hård Nevonen, Joel Magnusson, Benjamin Vafaeian, Lovisa Jonassen, Vilma Henricsson, David Olander and Emelie Schoning.

Related

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025

Vinge advises Advania in connection with the acquisition of atNorth HPC AB

Vinge has advised Advania, one of the leading IT companies in the Nordic region, in connection with the acquisition of atNorth HPC AB. The acquisition strengthens Advania's presence within high-performance computing (HPC).
October 03, 2025